{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/menieres-disease/prescribing-information/cyclizine/","result":{"pageContext":{"chapter":{"id":"73881eee-9a58-575f-9d06-545fa1f67335","slug":"cyclizine","fullItemName":"Cyclizine","depth":2,"htmlHeader":"<!-- begin field 88cbab3d-5bf5-4305-9485-03df147238f4 --><h2>Cyclizine</h2><!-- end field 88cbab3d-5bf5-4305-9485-03df147238f4 -->","summary":"","htmlStringContent":"<!-- begin item af974e5f-8efe-4ac6-b9e6-685ad8db9f58 --><!-- end item af974e5f-8efe-4ac6-b9e6-685ad8db9f58 -->","topic":{"id":"c2b20ab8-7e5a-5868-9804-8a9d6a2cb567","topicId":"193a65ca-1981-44e6-a5d3-781aa5010b2c","topicName":"Meniere's disease","slug":"menieres-disease","lastRevised":"Last revised in November 2017","chapters":[{"id":"16b06288-e565-5867-9311-37b626851eb0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"47494f3b-a0fd-53b2-8613-2cd38f1a11dd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"371c2958-24a9-5d9c-ae14-b7539d491674","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d13d990c-bded-5655-aa70-40268a150cbd","slug":"changes","fullItemName":"Changes"},{"id":"c184f0c8-2419-565f-ab73-a1a5591fc29d","slug":"update","fullItemName":"Update"}]},{"id":"9c1b726a-8066-5632-89ef-7764e1edd1d3","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8ee08c5c-67dd-57f0-b666-7d874024d8ed","slug":"goals","fullItemName":"Goals"},{"id":"7fd84935-e76b-56af-b285-b58ed2a8ecc2","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"981ad1f7-1003-50fc-8e49-411ea1ff34d4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4307ba4c-2b7b-54c0-9103-71e4a18f16ac","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"416a0198-b8a8-5272-8684-3aa5a380fc74","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2221f812-317a-569e-a4bc-0183f833d0f7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"272bf558-6edb-531a-a2d4-4b19639383ad","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"25e37eb8-40b6-5b11-b9d3-4fe5378e1524","slug":"definition","fullItemName":"Definition"},{"id":"65d7cb18-66af-5447-8401-2c8e24d64dd4","slug":"cause","fullItemName":"Cause"},{"id":"4f2a2237-790f-5b99-9650-34b58a75512e","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ed8dbd0f-7c6b-53bf-a2b9-77006586ab7e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a4342e8b-12e6-56d8-a716-190cac3ce652","slug":"complications","fullItemName":"Complications"},{"id":"5b357eed-7df9-57ca-9c0d-0511ecf6f601","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"318e7c3d-c3c6-5a60-be9d-9179e643d3fb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0ae90882-dae2-56da-b987-8bca0eefb6b3","slug":"suspecting-menieres-disease","fullItemName":"Suspecting Meniere's disease"},{"id":"7fc93a60-260c-5030-a14e-d6375907f198","slug":"making-a-diagnosis","fullItemName":"Making a diagnosis"},{"id":"73c5b8af-f846-541f-a7d9-48e2c6b9679c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3f2772f3-1ee5-5ca8-8c0c-bb2454b53670","fullItemName":"Management","slug":"management","subChapters":[{"id":"ed30823a-3e70-58a0-9411-f17351fb2c44","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"0b1be20b-b94c-56a6-a221-cbea038b74ec","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"2054a7c4-97a4-57e7-a3de-05ea67cfa502","slug":"betahistine","fullItemName":"Betahistine"},{"id":"2e656ebe-784a-562f-8aca-85a4aa0f56bb","slug":"cinnarizine","fullItemName":"Cinnarizine"},{"id":"73881eee-9a58-575f-9d06-545fa1f67335","slug":"cyclizine","fullItemName":"Cyclizine"},{"id":"584ce48e-7ea7-5ee0-874b-1c99ccbdb8fa","slug":"prochlorperazine","fullItemName":"Prochlorperazine"},{"id":"0c353f7c-323c-5e3b-9872-1e6533f5abad","slug":"promethazine-teoclate","fullItemName":"Promethazine teoclate"}]},{"id":"5de25a19-1810-510b-ba6b-c9b9979fb4c6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f893c00d-a15b-572d-8042-6164f0ee4141","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"18f58ee1-0ff6-5c45-b4a3-5f2f22070e03","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"41de5190-f85f-57eb-81a1-fa4aad3af7b5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"9e4161b0-4719-5539-99e5-e094855a17d0","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5a5f7056-1236-5638-904d-dce7e2b843af","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2b63dcde-7589-5a5a-b219-7f2ff2e0b527","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8a8e9bf2-d409-5815-8467-31e3a6379930","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0b1be20b-b94c-56a6-a221-cbea038b74ec","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"e91e633b-7d90-5d8e-b81a-ffb638a419ba","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field b41e4e51-aedf-4fba-a9a5-a81000ee61ca --><h3>What dosage of cyclizine should I prescribe?</h3><!-- end field b41e4e51-aedf-4fba-a9a5-a81000ee61ca -->","summary":"","htmlStringContent":"<!-- begin item 6fca181d-a40f-41b3-a66f-a81000ee5c69 --><!-- begin field 49fbd689-a4a0-4ace-865b-a81000ee61ca --><ul><li>For nausea, vomiting, vertigo, or labyrinthine disorders, prescribe cyclizine 50 mg orally up to three times a day. </li><li>If the oral route is not appropriate, cyclizine 50 mg by intramuscular injection can be given up to three times a day. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">ABPI Medicines Compendium, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">ABPI Medicines Compendium, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">BNF 74, 2017</a>]</p><!-- end field 49fbd689-a4a0-4ace-865b-a81000ee61ca --><!-- end item 6fca181d-a40f-41b3-a66f-a81000ee5c69 -->","subChapters":[]},{"id":"916837be-b86f-5b16-a340-0f542a35389e","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 1a1e80ce-9dd6-4fed-bcfc-a81000ee9bd1 --><h3>What are the contraindications and cautions when prescribing cyclizine?</h3><!-- end field 1a1e80ce-9dd6-4fed-bcfc-a81000ee9bd1 -->","summary":"","htmlStringContent":"<!-- begin item cafe8a10-5b6c-4309-89cb-a81000ee9a48 --><!-- begin field fd3eafe2-f724-4442-88f3-a81000ee9bd1 --><ul><li><strong>Do not prescribe cyclizine to people with:</strong><ul><li>Hypersensitivity to cyclizine or its excipients.</li><li>Severe liver disease — increased risk of coma.</li><li>Porphyria.</li></ul></li><li><strong>Prescribe cyclizine with caution to people with:</strong><ul><li>Prostatic hypertrophy, urinary retention, susceptibility to angle-closure glaucoma, and pyloroduodenal obstruction.</li><li>Hepatic disease.</li><li>Epilepsy.</li><li>Severe heart failure or acute myocardial infarction — cyclizine may cause a fall in cardiac output associated with increases in heart rate, mean arterial pressure, and pulmonary wedge pressure.</li><li>Phaeochromocytoma.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">ABPI Medicines Compendium, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">BNF 74, 2017</a>] </p><!-- end field fd3eafe2-f724-4442-88f3-a81000ee9bd1 --><!-- end item cafe8a10-5b6c-4309-89cb-a81000ee9a48 -->","subChapters":[]},{"id":"c89208df-86ba-503c-b265-a5b012626b8f","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 70ac5d1f-0f08-4cf3-956f-a81000eecde6 --><h3>What are the adverse effects of cyclizine?</h3><!-- end field 70ac5d1f-0f08-4cf3-956f-a81000eecde6 -->","summary":"","htmlStringContent":"<!-- begin item a775f4c4-c30a-453d-a4b5-a81000eecc8b --><!-- begin field 6dbe6d48-e217-4e45-adaa-a81000eecde6 --><ul><li><strong>Drowsiness</strong> is a significant adverse effect with most of the older antihistamines (such as cyclizine), especially with high doses or in the elderly.</li><li><strong>Other adverse effects include:</strong><ul><li>Psychiatric — restlessness, nervousness, euphoria, disorientation, insomnia, and auditory and visual hallucinations.</li><li>Neurological — headache, dystonia, dyskinesia, extrapyramidal motor disturbances, tremor, seizures, dizziness, somnolence and decreased consciousness, speech disorders (transient), paraesthesia, and generalized chorea.</li><li>Cardiovascular — tachycardia, palpitations, arrhythmias, hypertension, and hypotension.</li><li>Respiratory — bronchospasm and apnoea.</li><li>Gastrointestinal and hepatic — dry mouth, nose and throat; constipation; increased gastric reflux; nausea, vomiting, and diarrhoea; stomach pain; loss of appetite; hepatic dysfunction; cholestatic jaundice and hepatitis.</li><li>Skin — rashes, urticaria, angio-oedema, allergic skin reactions, and fixed drug eruption photosensitivity.</li><li>Musculoskeletal — twitching and muscle spasms.</li><li>Immune system — hypersensitivity reactions, including anaphylaxis.</li><li>Blood and lymphatic system — agranulocytosis, haemolytic anaemia, leucopenia, and thrombocytopenia.</li><li>Others — tinnitus, blurred vision and oculogyric crisis, and urinary retention.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">ABPI Medicines Compendium, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">BNF 74, 2017</a>] </p><!-- end field 6dbe6d48-e217-4e45-adaa-a81000eecde6 --><!-- end item a775f4c4-c30a-453d-a4b5-a81000eecc8b -->","subChapters":[]},{"id":"5565d112-81ac-5e64-a59c-19795a158833","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 7736d062-16e9-4232-a55c-a81000eef045 --><h3>What drug interactions occur with cyclizine?</h3><!-- end field 7736d062-16e9-4232-a55c-a81000eef045 -->","summary":"","htmlStringContent":"<!-- begin item 1f0c6929-19b9-448e-b785-a81000eeee1b --><!-- begin field 6977bca8-3214-4c82-a0b2-a81000eef045 --><ul><li>Important drug interactions with cyclizine include:<ul><li>Alcohol — the anti-emetic effect of cyclizine may increase the toxic effects of alcohol.</li><li>Antimuscarinic drugs — there is a risk of increased antimuscarinic adverse effects when cyclizine is given with other antimuscarinic drugs. </li><li>Central nervous system (CNS) depressant drugs — cyclizine may have additive effects with other CNS depressants, such as opioid analgesics.</li><li>Ototoxic drugs — cyclizine may disguise signs indicating the onset of damage caused by ototoxic drugs (such as aminoglycoside antibiotics).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">ABPI Medicines Compendium, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">BNF 74, 2017</a>] </p><!-- end field 6977bca8-3214-4c82-a0b2-a81000eef045 --><!-- end item 1f0c6929-19b9-448e-b785-a81000eeee1b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}